Suppr超能文献

患有CD87+急性髓性白血病患者的恶性祖细胞对白喉毒素-尿激酶融合蛋白敏感。

Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.

作者信息

Frankel Arthur E, Beran Miloslav, Hogge Donna E, Powell Bayard L, Thorburn Andrew, Chen Yong Q, Vallera Daniel A

机构信息

Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.

出版信息

Exp Hematol. 2002 Nov;30(11):1316-23. doi: 10.1016/s0301-472x(02)00925-6.

Abstract

In previous studies, we demonstrated that the diphtheria toxin-urokinase fusion protein DTAT was selectively toxic to acute myeloid leukemia (AML) cell lines overexpressing the CD87 urokinase receptor. In the present study, we analyzed the sensitivity of patient leukemic progenitors to DTAT and correlated the sensitivity with CD87 expression. We isolated leukemic blasts by density gradient centrifugation and performed immunophenotyping by flow cytometry and blast sensitivity measurements by inhibition of cell proliferation and colony formation in semisolid media. We found CD87 overexpression in 18 (25%) of 71 patient leukemic blast samples, including 18 (28%) of 64 myeloid malignancies and 0 (0%) of 7 lymphoid malignancies. DTAT was toxic to patient leukemic blasts by both proliferation inhibition (IC50 <or=1 nM DTAT in 18/69 evaluable samples) and colony formation inhibition (>85% inhibition by 10 nM DTAT in 11/41 evaluable samples). Only AML and chronic myeloid leukemia (CML) blast crisis blasts (18/61 [30%]) were sensitive to DTAT by the proliferation inhibition assay. Lymphoid leukemia and chronic phase CML/chronic myelomonocytic leukemia (CMML) progenitors were insensitive to DTAT by the proliferation inhibition assay (n = 7 and n = 3, respectively). Similarly, normal marrow progenitors were insensitive to DTAT by both proliferation inhibition (n = 2) and colony inhibition (n = 5) assays. The DTAT toxicity measured by both proliferation inhibition assay and colony inhibition assay correlated with CD87 density (p < 0.0001 and p = 0.001, respectively). DTAT toxicity results were similar for leukemic blasts measured by either of the two assays (p = 0.0002). This study provides the first evidence that a urokinase receptor targeted diphtheria fusion protein is toxic to patient AML blasts. The work also suggests that blast proliferation assays yield similar responses to leukemia colony-forming cell colony assays.

摘要

在先前的研究中,我们证明白喉毒素-尿激酶融合蛋白DTAT对过表达CD87尿激酶受体的急性髓系白血病(AML)细胞系具有选择性毒性。在本研究中,我们分析了患者白血病祖细胞对DTAT的敏感性,并将敏感性与CD87表达相关联。我们通过密度梯度离心分离白血病原始细胞,并通过流式细胞术进行免疫表型分析,以及通过在半固体培养基中抑制细胞增殖和集落形成来测量原始细胞敏感性。我们在71例患者白血病原始细胞样本中的18例(25%)中发现CD87过表达,包括64例髓系恶性肿瘤中的有18例(28%),以及7例淋巴系恶性肿瘤中的0例(0%)。通过增殖抑制(在18/69个可评估样本中DTAT的IC50≤1 nM)和集落形成抑制(在11/41个可评估样本中10 nM DTAT的抑制率>85%),DTAT对患者白血病原始细胞均具有毒性。通过增殖抑制试验,仅AML和慢性髓系白血病(CML)急变期原始细胞(18/61 [30%])对DTAT敏感。通过增殖抑制试验,淋巴系白血病以及CML/慢性粒单核细胞白血病(CMML)慢性期祖细胞对DTAT不敏感(分别为n = 7和n = 3)。同样,正常骨髓祖细胞通过增殖抑制试验(n = 2)和集落抑制试验(n = 5)对DTAT均不敏感。通过增殖抑制试验和集落抑制试验测得的DTAT毒性均与CD87密度相关(分别为p < 0.0001和p = 0.001)。通过两种试验中的任何一种测量的白血病原始细胞的DTAT毒性结果相似(p = 0.0002)。本研究提供了首个证据,即一种靶向尿激酶受体的白喉融合蛋白对患者AML原始细胞具有毒性。该研究还表明,原始细胞增殖试验与白血病集落形成细胞集落试验产生相似的反应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验